By Sherri Oslick —

On Thursday, Celera of Rockville, MD and Alameda, CA, an Applera Corporation business, announced that it would acquire Atria Genetics, Inc. of San Fransisco, CA for approximately $33 million cash.  Atria Genetics is a private company that has developed a line of human leukocyte antigen (HLA) testing products that are used for identifying potential donors in the matching process for bone marrow transplantation.  The acquisition is expected to be completed during the second quarter of Celera’s fiscal 2008.  Abbott Molecular, a division of Abbott Laboratories, markets and distributes Atria Genetics’ current HLA sequencing-based typing products through its alliance with Celera.

For additional information regarding the acquisition, please see:

• Celera’s press release